| Literature DB >> 33235473 |
Pei-Wen Wu1,2, Ta-Jen Lee1, Chun-Hua Wang3, Chi-Che Huang1,4, Po-Hung Chang1,4, Chia-Hsiang Fu1,4, Chien-Chia Huang1,4.
Abstract
INTRODUCTION: Most patients with asthma, either allergic or non-allergic, usually exhibit some level of concurrent rhinitis. Treatments for rhinitis and asthma can affect both conditions.Entities:
Keywords: SNOT-22; asthma; patient-reported outcome measure; quality of life; rhinitis
Year: 2020 PMID: 33235473 PMCID: PMC7678713 DOI: 10.2147/JAA.S284111
Source DB: PubMed Journal: J Asthma Allergy ISSN: 1178-6965
Clinical Characteristics of the Study Population
| ACT Improvement | P value# | |||
|---|---|---|---|---|
| Total | Yes | No | ||
| Cases (n) | 28 | 13 | 11 | |
| Age (years) | 54.3 ± 2.7 | 58.4 ± 3.4 | 53.3 ± 3.8 | 0.384 |
| Male: Female (n: n) | 21: 7 | 9: 4 | 9: 2 | 0.478 |
| Atopy (n) | 11 | 3 | 8 | 0.015† |
| Serum IgE (IU/mL) | 234.4 ± 83.9 | 230.4 ± 122.6 | 307.4 ± 158.6 | 0.235 |
| SNOT-22 score | 54.7 ± 5.3 | 59.7 ± 7.7 | 51.6 ± 8.4 | 0.582 |
| ACT score | 20.7 ± 0.9 | 17.9 ± 1.6 | 24.7 ± 0.2 | <0.001* |
| FVC (%) predicted | 79.2 ± 3.7 | 76.2 ± 5.5 | 85.1 ± 6.6 | 0.297 |
| FEV1 (%) predicted | 68.5± 4.2 | 60.9± 6.0 | 77.7± 6.3 | 0.046* |
| FEV1/FVC (%) predicted | 84.1 ± 3.4 | 78.2 ± 4.8 | 86.6 ± 4.4 | 0.222 |
| Anti-asthma medication (n) | 0.148 | |||
| Step 1 (as-needed SABA) | 0 | 0 | 0 | |
| Step 2 (low dose ICS) | 9 | 2 | 7 | |
| Step 3 (low dose ICS + LABA) | 7 | 5 | 2 | |
| Step 4 (medium/high dose ICS + LABA) | 5 | 3 | 2 | |
| Step 5 (anti-IgE or OCS) | 3 | 3 | 0 | |
Notes: Data presented as mean ± standard error unless otherwise indicated. #Comparison between patients with and without Asthma Control Test (ACT) improvement after surgery; †p < 0.05 (chi-squared test); *p < 0.05 (Mann–Whitney U-test).
Abbreviations: IgE, immunoglobulin E; SNOT-22, Sino-Nasal Outcome Test-22; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; SABA, short-acting beta2-agonist; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; OCS, oral corticosteroid.
Figure 1A strong correlation was observed between the Asthma Control Test (ACT) and Sino-Nasal Outcome Test-22 (SNOT-22) scores preoperatively (A) and 3 months postoperatively (B). ACT score was also well correlated with the predicted forced expiratory volume in 1 s (FEV1) (C), but not with total serum immunoglobulin (IgE) level (D). *p < 0.05; **p < 0.001 (Spearman correlation).
Figure 2Nasal surgery improved sinonasal symptoms (A), but not asthma control (B) and the use of anti-asthma medication (C). The symbols represented patients with the same step of anti-asthma medication were overlapped. **p < 0.001 (Wilcoxon signed-rank test).
Figure 3There was no significant difference between preoperative (pre-op) and postoperative (post-op) results of pulmonary function testing, including predicted forced vital capacity (FVC) (A), forced expiratory volume in 1 s (FEV1) (B) and FEV1/FVC (C).
Figure 4The change in Asthma Control Test (ACT) scores were inversely correlated with the preoperative (pre-op) ACT score (A). When compared between patients with and without improvement in ACT after surgery, patients with postoperative ACT improvement had a worse pre-op ACT score (B) and predicted forced expiratory volume in 1 s (FEV1) (C). There was no difference in pre-op Sino-Nasal Outcome Test-22 (SNOT-22) score (D). *p < 0.05; **p < 0.001 (Spearman correlation and Mann–Whitney U-test).